YahooSeptember 15, 2026 at 9:00 AM NYLast Month
Clene Announces $4 Million Registered Direct Offering
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
